![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KM Hurlbut, RM Maiorino, M Mayersohn, RC Dart, DC Bruce and HV Aposhian
Department of Pharmacology and Toxicology, University of Arizona, Tucson.
The pharmacokinetics of 2,3-dimercaptopropane-1-sulfonate (DMPS), an effective chelating agent for mercury, were determined in five healthy adults after i.v. administration of 3.0 mg/kg of DMPS. DMPS is rapidly transformed to disulfide forms; 15 min after administration, only 12% of the total DMPS detected in blood was present as the parent drug. DMPS and its metabolites were eliminated primarily by the kidneys. By 96 hr after administration, 12% of the total DMPS found in the urine was excreted as the parent drug (10% of the administered dose) and 88% was excreted as disulfide metabolites (74% of the administered dose). The disposition of parent drug was described by a biexponential equation with an elimination half-life of 1.8 hr. By contrast, the elimination half-life of total DMPS was 20 hr. The oral bioavailability of the parent drug was found in a separate study to be 39%. Mercury excretion in healthy volunteers correlated well with the urinary excretion of both the parent drug (r2 = .94) and the disulfide metabolites (r2 = .96).
This article has been cited by other articles:
|
|
 |
|
  Y. Xu, Y. Wang, Q. Zheng, B. Li, X. Li, Y. Jin, X. Lv, G. Qu, and G. Sun Clinical Manifestations and Arsenic Methylation after a Rare Subacute Arsenic Poisoning Accident Toxicol. Sci., June 1, 2008; 103(2): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lungkaphin, V. Chatsudthipong, K. K. Evans, C. E. Groves, S. H. Wright, and W. H. Dantzler Interaction of the metal chelator DMPS with OAT1 and OAT3 in intact isolated rabbit renal proximal tubules Am J Physiol Renal Physiol, January 1, 2004; 286(1): F68 - F76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Islinger, M. Gekle, and S. H. Wright Interaction of 2,3-Dimercapto-1-propane Sulfonate with the Human Organic Anion Transporter hOAT1 J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 741 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Pingree, P. L. Simmonds, and J. S. Woods Effects of 2,3-Dimercapto-1-propanesulfonic Acid (DMPS) on Tissue and Urine Mercury Levels following Prolonged Methylmercury Exposure in Rats Toxicol. Sci., June 1, 2001; 61(2): 224 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gonzalez-Ramirez, M. Zuniga-Charles, A. Narro-Juarez, Y. Molina-Recio, K. M. Hurlbut, R. C. Dart, and H. V. Aposhian DMPS (2,3-Dimercaptopropane-1-sulfonate, Dimaval) Decreases the Body Burden of Mercury in Humans Exposed to Mercurous Chloride J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 8 - 12. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
